EUVIMEDEUVIMED entdecken
Crossref

RNF216 Drives Hepatocellular Carcinoma Progression by Ubiquitin‐Dependent Degradation of the Tumour Suppressor CYLD

Si Yang iD, Qing Liu, Shaohua Li, Yi Zheng, Yujiao Deng iD, Lifang Zhao, Huahong Xie iD

Liver International · 2026-12 · 46 (12)

DOI: 10.1111/liv.70949 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, online erschienen am 11.11.2026. Verfasst von Si Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Digestive Diseases, Xijing Hospital, Air Force Medical University, Xi'an, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Deubiquitinating Enzyme CYLD, Ubiquitin-Protein Ligases. Die Arbeit nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Innovation Capability Support Program of Shaanxi, Health Research Fund of Shaanxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims The role of ubiquitination in the progression of hepatocellular carcinoma (HCC) remains unclear. This study investigated ubiquitination heterogeneity across cell types and the function of the E3 ubiquitin ligase RNF216 in HCC.

Methods

To map the cellular landscape and ubiquitination heterogeneity, we performed single‐cell RNA sequencing (scRNA‐seq) on 10 HCC samples. Bioinformatics analysis identified RNF216 as a key prognostic ubiquitination‐related gene (URG), validated in public datasets and an internal cohort by immunohistochemistry. Functional assays (CCK‐8, wound healing, and Transwell migration and invasion) and a xenograft model were performed in HCC cells. The mechanisms were explored using Western blotting, co‐immunoprecipitation, ubiquitination assays, and immunofluorescence.

Results

ScRNA‐seq revealed the highest ubiquitination activity in T and B cells and the lowest in hepatocytes. Differential expression analysis between high‐ and low‐ubiquitination groups identified 75 URGs. Among these, RNF216 was significantly upregulated in HCC and correlated with advanced stage and unfavourable prognosis, prompting its selection for further functional validation. RNF216 knockdown suppressed proliferation, migration, invasion, and EMT in both Huh7 and MHCC97H cells, and inhibited tumour growth in vivo. Mechanistically, RNF216 directly interacted with CYLD and promoted its ubiquitination and proteasomal degradation. CYLD re‐expression in RNF216‐overexpressing Huh7 cells significantly reversed RNF216‐induced increases in proliferation, migration, invasion, and EMT. Immunofluorescence demonstrated that RNF216 promotes β‐catenin nuclear translocation in a CYLD‐dependent manner.

Conclusions

RNF216 promotes HCC progression through ubiquitination and degradation of CYLD, leading to β‐catenin accumulation and EMT. RNF216 may serve as a therapeutic target for HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsDeubiquitinating Enzyme CYLDUbiquitin-Protein LigasesHumansAnimalsUbiquitinationDisease ProgressionMiceCell Line, TumorCell MovementMaleGene Expression Regulation, NeoplasticCell ProliferationProteolysisEpithelial-Mesenchymal TransitionFemaleMice, Nude

Stichwörter der Autor:innen

CYLDE3 ubiquitin ligaseRNF216hepatocellular carcinomasingle‐cell RNA sequencingubiquitination

Substanzen

Deubiquitinating Enzyme CYLDCYLD protein, humanUbiquitin-Protein Ligases

Autor:innen und Institutionen

  • Department of Digestive Diseases, Xijing Hospital, Air Force Medical University, Xi'an, China.
  • Department of Oncology, Xijing Hospital, Air Force Medical University, Xi'an, China.
  • Department of Hepatology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • Department of Gastroenterology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • State Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Air Force Medical University, Xi'an, China.

ORCID-Profile: Si Yang, Yujiao Deng, Huahong Xie

Förderung

  • National Natural Science Foundation of China
  • Innovation Capability Support Program of Shaanxi
  • Health Research Fund of Shaanxi Province
  • Discipline Promoting Plan of Xijing Hospital

Zitieren

APA

Yang, S., Liu, Q., Li, S., Zheng, Y., Deng, Y., Zhao, L., & Xie, H. (2026). RNF216 Drives Hepatocellular Carcinoma Progression by Ubiquitin‐Dependent Degradation of the Tumour Suppressor CYLD. Liver International, 46(12). https://doi.org/10.1111/liv.70949

Vancouver

Yang S, Liu Q, Li S, Zheng Y, Deng Y, Zhao L, et al. RNF216 Drives Hepatocellular Carcinoma Progression by Ubiquitin‐Dependent Degradation of the Tumour Suppressor CYLD. Liver International. 2026;46(12). doi:10.1111/liv.70949

BibTeX
@article{Yang2026,
  author = {Yang, Si and Liu, Qing and Li, Shaohua and Zheng, Yi and Deng, Yujiao and Zhao, Lifang and Xie, Huahong},
  title = {RNF216 Drives Hepatocellular Carcinoma Progression by Ubiquitin‐Dependent Degradation of the Tumour Suppressor CYLD},
  journal = {Liver International},
  year = {2026},
  volume = {46},
  number = {12},
  doi = {10.1111/liv.70949}
}
Kostenlos starten →